Lamotrigine Tablet
Product Images NDC 51655-855

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 51655-855). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655-855-52 (51655 855 52 Rev A 02 23)

51655-855-52 (51655 855 52   Rev A 02 23)
Packaging label for Lamotrigine Tablets, USP 25 mg, oral tablets. The label states a quantity of 30 tablets and indicates prescription use only (Rx Only). It includes storage information and manufacturer details, showing the labeler as Northwind Pharmaceuticals with additional packaging and lot information.*
FDA Label Image

Structure (5a15187f B147 4147 A4ef 0e3e5de73cb6 01)

Structure (5a15187f B147 4147 A4ef 0e3e5de73cb6 01)
Chemical structure of lamotrigine, showing its molecular framework with chlorine atoms and amino groups attached to the aromatic rings.*
FDA Label Image

Graph (5a15187f B147 4147 A4ef 0e3e5de73cb6 02)

Graph (5a15187f B147 4147 A4ef 0e3e5de73cb6 02)
A Kaplan-Meier survival curve chart showing failure probability percentage over weeks. Two curves are displayed, labeled Lamotrigine and Placebo, illustrating the difference in failure probabilities between the two groups during a study period up to about 100 weeks. The chart includes censored data points marked with plus signs.*
FDA Label Image

Graph (5a15187f B147 4147 A4ef 0e3e5de73cb6 03)

Graph (5a15187f B147 4147 A4ef 0e3e5de73cb6 03)
A Kaplan-Meier failure probability curve comparing Lamotrigine and placebo over approximately 80 weeks. The y-axis represents failure probability in percentage, and the x-axis shows time in weeks. Two distinct curves are labeled for Placebo and Lamotrigine, with censored data points marked. The graph illustrates differences in failure probability between the two groups over time.*
FDA Label Image

Image 2 (5a15187f B147 4147 A4ef 0e3e5de73cb6 04)

FDA Label Image

Image (708290c4 B959 47cc 95a1 38a6270297e5 1119 2)

Image (708290c4 B959 47cc 95a1 38a6270297e5 1119 2)
An illustration showing dimensional drawings of Lamotrigine tablets for various strengths: 25 mg, 100 mg, 150 mg, and 200 mg. Each strength is depicted with two views of the tablet, labeled as upper face and lower face, displaying the tablet’s imprint and shape characteristics.*
FDA Label Image

Image (708290c4 B959 47cc 95a1 38a6270297e5 1119 3)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.